Author

F. Musarrat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Dahai· 1 shared K. G. Kousoulas· 1 shared K. Kousoulas· 1 shared R. Nabi· 1 shared S. Jois· 1 shared V. Chouljenko· 1 shared V. N. Chouljenko· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Dahai

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cellular and Viral Determinants of HSV-1 Entry and Intracellular Transport towards Nucleus of Infected Cells

F. Musarrat, V. N. Chouljenko, K. G. Kousoulas

This paper identifies Akt and kinase C inhibitors that block HSV-1 entry and capsid transport to the nucleus, and shows viral proteins UL37 and Vp5 interact with dynein components during transport.

bioRxiv · Jan 4, 2021 · PreprintMicrobiology

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections

F. Musarrat, V. Chouljenko, R. Nabi, A. Dahai, S. Jois, K. Kousoulas

This paper shows that nelfinavir mesylate inhibits SARS-CoV-2 S glycoprotein-mediated cell fusion, suggesting its potential as an antiviral against COVID-19.

bioRxiv · Apr 24, 2020Microbiology